Characteristics and Outcome of Connective Tissue Diseases in Patients with Sickle-Cell Disease: Report of 30 Cases

Seminars in Arthritis and Rheumatism

Volumn 38, Issue 3, 2008, Pages 228-240

  Michel, M ^a   Habibi, A ^a   Godeau, B ^a   Bachir, D ^a   Lahary, A ^b   Galacteros, F ^a   Fifi Mah, A ^c   Arfi, S ^c  

^a HENRI MONDOR HOSPITAL   (France)

^b ROUEN UNIVERSITY HOSPITAL   (France)

^c Pierre Zobda Quitman Hospital   (Martinique)

Author keywords

blood stream infections; connective tissue diseases; rheumatoid arthritis; sickle cell disease; systemic lupus erythematosus

Indexed keywords

ADALIMUMAB; AUTOANTIBODY; AZATHIOPRINE; BOSENTAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; ETANERCEPT; GOLD; HEMOGLOBIN C; HEMOGLOBIN S; HYDROXYCHLOROQUINE; HYDROXYUREA; INFLIXIMAB; ISONIAZID; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; PENICILLAMINE; PREDNISOLONE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RIFAMPICIN; RITUXIMAB; SALAZOSULFAPYRIDINE; TRIAMCINOLONE HEXACETONIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; WARFARIN;

ACUTE CHEST SYNDROME; ADULT; ARTICLE; AVASCULAR NECROSIS; BLOOD TRANSFUSION; BLOOD VESSEL OCCLUSION; BONE RADIOGRAPHY; BRAIN HEMORRHAGE; CAUSE OF DEATH; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL FEATURE; CONNECTIVE TISSUE DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENTEROBACTER INFECTION; ESCHERICHIA COLI; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LIVER TOXICITY; LOW DRUG DOSE; MALE; MORTALITY; NEPHROTIC SYNDROME; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RETINOPATHY; RHEUMATOID ARTHRITIS; SEPSIS; SICKLE CELL ANEMIA; SJOEGREN SYNDROME; SKIN MANIFESTATION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STEROID THERAPY; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TUBERCULOSIS;

ADULT; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; ARTHRITIS, RHEUMATOID; BLOOD TRANSFUSION; DRUG THERAPY, COMBINATION; FEMALE; FRANCE; GLUCOCORTICOIDS; HUMANS; HYDROXYUREA; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; METHOTREXATE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 56649095847     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2007.10.003     Document Type: Article

References (38)

1. Steinberg M.H. Management of sickle cell disease. New Engl J Med 340 (1999) 1021-1029
2. Almeida A., and Roberts I. Bone involvement in sickle cell disease. Br J Haematol 129 (2005) 482-490
3. Nistala K., and Murray K.J. Co-existent sickle cell disease and juvenile rheumatoid arthritis. Two cases with delayed diagnosis and severe destructive arthropathy. J Rheumatol 28 (2001) 2125-2128
4. Katsanis E., Hsu E., Luke K.H., and Mc Kee J.A. Systemic lupus and sickle hemoglobinopathies: a report of two cases and review of literature. Am J Hematol 25 (1987) 211-214
5. Marino C., and Mc Donald E. Rheumatoid arthritis in a patient with sickle cell disease. J Rheumatol 17 (1990) 970-972
6. Kaloterakis A., Filiotou A., Haziyannis S., Vaiopoulos G., and Lutradi-Anagnostou A. Sickle/beta-thalassemia and systemic lupus erythematosus. Lupus 8 (1999) 778-779
7. Khalidi N.A., Ajmani H., and Varga J. Coexisting systemic lupus erythematosus and sickle cell disease: a diagnostic and therapeutic challenge. J Clin Rheumatol 11 (2005) 86-92
8. Shetty A.K., Kumart S.R., Gedalia A., and Warrier R.P. Sickle cell anemia with systemic lupus erythematosus: response to hydroxyurea therapy. J Pediatr Hematol Oncol 20 (1998) 335-337
9. Eissa M.M., Lawrence J.M., Mc Kenzie L., Little F.M., Mankad V.N., and Yang Y.M. Systemic lupus erythematosus in a child with sickle cell disease. South Med J 88 (1995) 1176-1178
10. Tan E.M., Cohen A.S., Fries J.F., Masi A.T., Mc Shane D.J., Rothfield N.F., et al. The 1982 revised criteria for the classification of SLE. Arthritis Rheum 25 (1982) 1271-1277
11. Hochberg M. Updating the American College of Rheumatology revised criteria for classification of systemic lupus erythematosus. Arthritis Rheum 40 (1997) 1725-1734
12. Arnett F.C., Edworthy S.M., Block D.A., McShane D.J., Fries J.F., Cooper N.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31 (1988) 315-324
13. Vitali C., Bombardieri S., and Moutsopoulos H.M. Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum 36 (1993) 340-347
14. Hebbel R.P., Boogaerts M.A.B., Eaton J.W., and Steinberg M.H. Erythrocyte adherence to endothelium in sickle-cell anemia. New Engl J Med 302 (1980) 992-995
15. Lee K., Gane P., Roudhot-Thoraval F., Godeau B., Bachir D., Bernaudin F., et al. The non expression of CD36 on reticulocytes and mature red blood cell does not modify the clinical course of patients with sickle cell anemia. Blood 98 (2001) 966-971
16. Platt O.S., Thorington B.D., Brambilla D.J., Miller P.F., Rosse W.F., Vichinsky E., et al. Pain in sickle cell disease: rates and risk factors. New Engl J Med 325 (1992) 11-16
17. Felson D.T., Anderson J.J., Boers M., Bombardier C., Chernoff M., Fried B., et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis in clinical trial. Arthritis Rheum 36 (1993) 729-740
18. Halasa N.B., Shankar S.M., Talbot T.R., Arbogast P.G., Mitchel E.F., Wang W.C., et al. Incidence or invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis 44 (2007) 1428-1433
19. Zarrouk V., Habibi A., Zahar J.R., Roudot-Thoraval F., Bachir D., Brun-Buisson C., et al. Bloodstream infection in adults with sickle cell disease: association with venous catheters. Staphyloccus aureus, and bone-joint infections. Medicine 85 (2006) 43-48
20. Wilson W.A., Deceulaer K., and Morgan A.G. Sickle cell anemia, complement and systemic lupus erythematosus. Arthritis Rheum 22 (1979) 803
21. Koethe S.M., Casper J.T., and Rodey G.E. Alternative pathway activity in sera from patients with sickle cell disease. Clin Exp Immunol 23 (1976) 56-60
22. MacGregor A.J., Riste L.K., Hazes J.M., and Silman A.J. Low prevalence of rheumatoid arthritis in black-Caribbeans compared with whites in inner city Manchester. Ann Rheum Dis 53 (1994) 293-297
23. Molokhia M., and McKeigue P. Risk for disease in relation to ethnicity and admixture. Arthritis Res 2 (2000) 115-125
24. Molokhia M., McKeigue P.M., Cuadrado M., and Hughes G. Systemic lupus erythematosus in migrants from west Africa compared with Afro-Caribbean people in the UK. Lancet 357 (2001) 1414-1415
25. Mody G.M. Rheumatoid arthritis and connective tissue disorders: sub-Saharan Africa. Baillieres Clin Rheumatol 9 (1995) 31-44
26. Pathare A., Al Kindi A., Alnaqdy A., Daar S., Knox-Macaulay H., and Dennison D. Cytokine profile of sickle cell disease in Oman. Am J Hematol 77 (2004) 323-328
27. Hoppe C., Klitz W., D'Harlingue K., Cheng S., Grow M., Stainer L., et al. Confirmation of an association between the TNF (-308) promoter polymorphism and stroke risk in children with sickle cell anemia. Stroke 38 (2007) 2241-2246
28. Chulamoka L., Scholand S.J., Riggio J.M., Ballas S.K., Horn D., and DeSimone J.A. Bloodstream infection in hospitalized adults with sickle cell disease: a retrospective analysis. Am J Hematol 81 (2006) 723-728
29. Bernini J.C., Rogers Z.R., Sandler E.S., Reisch J.S., Quinn C.T., and Buchanan G.R. Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease. Blood 92 (1998) 3082-3089
30. Buchanan G.R. Infection. In: Embury S.H., Hebbel R.P., Mohandas N., et al. (Eds). Sickle Cell Disease Basic Principles and Clinical Practice vol. 38 (1994), Raven Press, New York 567-597
31. Griffin T.C., McIntire D., and Buchanan G.R. High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease. N Engl J Med 330 (1994) 733-737
32. Johnson K., Stastny J.F., and Rucknagel D.L. Fat embolism syndrome associated with asthma and sickle cell disease beta-thalassemia. Am J Hematol 46 (1994) 354
33. Gladman D.D., and Bombardier C. Sickle cell crisis following intraarticular steroid therapy for rheumatoid arthritis. Arthritis Rheum 30 (1987) 1065
34. Couillard S., Benkerrou M., Girot R., Brousse V., Ferster A., and Bader-Meunier B. Steroid treatment in children with sickle cell disease. Haematologica 92 (2007) 425-426
35. Strouse J.J., Hulbert M.L., DeBaun M.R., Jordan L.C., and James F. Primary hemorrhagic stroke in children with sickle cell disease is associated with recent transfusion and use of corticosteroids. Pediatrics 118 (2006) 1916-1924
36. Platt O.S., Brambilla D.J., Rosse W.F., Milner P.F., Castro O., Steinberg M.H., et al. Mortality in sickle cell disease-life expectancy and risk factors for early deaths. New Engl J Med 330 (1994) 1639-1644
37. Powars D.R., Chan L.S., Hiti H., Ramicone E., and Johnson C. Outcome of sickle cell anemia. A 4-decade observational study of 1056 patients. Medicine 84 (2005) 363-376
38. Perronne V., Roberts-Harewood M., Bachir D., Roudot-Thoraval F., Delord J.M., Thuret I., et al. Patterns of mortality in sickle cell disease in adults in France and England. Hematol J 3 (2002) 56-60